People who take GLP-1 medications before undergoing bariatric surgery don't sacrifice surgical results, and in fact achieve significantly greater total weight loss than either treatment alone. A major new study from NYU Grossman School of Medicine analyzed over 6,700 patients and found that combining medication with surgery produces the most dramatic outcomes, challenging the assumption that these two approaches compete rather than complement each other.

What Happens When You Combine GLP-1 Drugs With Bariatric Surgery?

Researchers examined patients who took semaglutide or tirzepatide (both GLP-1 receptor agonists) before having metabolic and bariatric surgery, comparing their results to patients who went straight to surgery without medication. The findings were striking. Patients on GLP-1 medications lost about 8% of their body weight in the months before surgery. After undergoing gastric bypass surgery, those same patients achieved total weight loss exceeding 25% of their starting weight. Those who had sleeve gastrectomy, a less invasive procedure, reached about 20% total weight loss.

For context, patients who skipped medication and went directly to surgery lost only 2% to 3% more weight after their procedures, meaning the GLP-1 pre-treatment didn't diminish surgical effectiveness at all. "Our findings show that metabolic and bariatric surgery continues to deliver substantial and durable weight loss in this population," explained the lead researcher.

"Patients are increasingly having surgery after GLP-1 therapy, making it important to understand how prior medical treatment may influence outcomes. Our findings show that metabolic and bariatric surgery continues to deliver substantial and durable weight loss in this population," said Karan R. Chhabra, MD, MSc, Assistant Professor of Surgery and Population Health at NYU Grossman School of Medicine.

Karan R. Chhabra, MD, MSc, Assistant Professor of Surgery and Population Health, NYU Grossman School of Medicine

The study analyzed electronic health records from nearly 6,700 patients who received GLP-1 prescriptions within six months before surgery, including 2,395 who underwent gastric bypass and 4,315 who had sleeve gastrectomy. These outcomes were compared with data from approximately 40,000 gastric bypass patients and over 87,000 sleeve gastrectomy patients who had no prior GLP-1 use. All data came from 2019 to 2025.

How Is Obesity Care Changing as GLP-1 Popularity Grows?

The rise of GLP-1 medications has dramatically reshaped the obesity treatment landscape. Bariatric surgery rates have declined significantly, dropping 46% among eligible patients between 2022 and 2025, according to research published in JAMA Surgery. The proportion of eligible patients actually undergoing surgery fell from 0.17% in late 2022 to 0.09% in the third quarter of 2025. Despite this decline, bariatric surgery hasn't disappeared; instead, it's being integrated into comprehensive obesity care centers that offer both medical and surgical options.

Rather than closing their doors, bariatric surgery practices are expanding their services. Hospital-based programs and private practices alike now offer integrated care that combines surgical expertise with GLP-1 medications, nutrition counseling, behavioral therapy, and other support services. This shift reflects a growing understanding among doctors that obesity is a chronic disease requiring multiple treatment tools, not a condition where patients must choose between medication or surgery.

"Bariatric surgery isn't dead. Choosing one tool or an isolated intervention is not where we are anymore," said Kevin Huguet, MD, MPH, a bariatric surgeon in St. Petersburg, Florida, and founder of the MIIS Weight Loss Institute.

Kevin Huguet, MD, MPH, Founder and Medical Director, MIIS Weight Loss Institute

Several major medical centers have pioneered this integrated model. Baton Rouge General opened the Louisiana Center for Bariatrics in 2023, where surgeons, obesity medicine specialists, and dietitians work collaboratively with referrals flowing in both directions. Providence Swedish Weight Loss Services in Seattle transitioned to a fully integrated program about five to six years ago and has seen patient volume grow, not decline, as a result.

Steps to Understanding Your Obesity Treatment Options

• Assess Your Starting Point: Work with your doctor to determine whether you're a candidate for GLP-1 medications, bariatric surgery, or both. Less than 1% of people eligible for weight-loss surgery currently receive it in any given year, often due to insurance barriers or a preference to try medication first.
• Consider a Comprehensive Approach: Look for obesity care centers that offer multiple treatment modalities rather than surgery-only or medication-only practices. These integrated programs can help you transition between treatments if needed and provide nutrition, behavioral, and psychological support alongside medical or surgical interventions.
• Plan for Long-Term Management: Understand that obesity treatment typically requires ongoing care. The research shows that about two-thirds of patients who use GLP-1 medications before surgery resume drug treatment within three years, suggesting that combining approaches may provide the most durable results.

What Does the Future of Obesity Care Look Like?

The integration of GLP-1 medications and bariatric surgery represents a fundamental shift in how doctors approach severe obesity. Rather than viewing these treatments as competing options, the medical community increasingly sees them as complementary tools in a comprehensive care strategy. This approach is becoming more common, though comprehensive integrated programs remain relatively uncommon compared to traditional surgery-only or medication-only practices.

One interesting finding from the research involves what happens after surgery. Patients who used GLP-1 medications before surgery were more likely to resume drug treatment afterward. Among gastric bypass patients, 44.1% restarted GLP-1 therapy within the first year, compared to 57.4% of sleeve gastrectomy patients. By three years, about two-thirds of all patients were back on GLP-1 medications. This pattern suggests that initiating medication before surgery may increase the likelihood of long-term or resumed use post-operatively, while patients who proceed directly to surgery may be less likely to require lifelong medication.

"As the use of GLP-1 drugs continues to rise, it's critical that patients and providers understand how these treatments fit into the broader care pathway, particularly for individuals who may benefit from metabolic and bariatric surgery. Medications may start the weight loss journey, but surgery remains the most effective and durable treatment for most patients with severe obesity," stated Richard M. Peterson, MD, MPH, FASMBS, President of the American Society for Metabolic and Bariatric Surgery.

Richard M. Peterson, MD, MPH, FASMBS, President, American Society for Metabolic and Bariatric Surgery

The data supporting this integrated approach is compelling. Over 270,000 bariatric surgeries were performed in 2023, the latest year with complete data available. While this number represents a decline from previous years, it still demonstrates substantial ongoing demand for surgical intervention, particularly among patients who don't achieve desired results with medication alone or cannot tolerate GLP-1 drugs.

For patients considering obesity treatment, the takeaway is clear: the old model of choosing between medication and surgery is outdated. Modern obesity care recognizes that these approaches work synergistically, and the most effective path forward often involves both, along with comprehensive support services. As more medical centers adopt this integrated model, access to combined treatment approaches should improve, offering patients more personalized options based on their individual needs and circumstances.